Journal
ADVANCED THERAPEUTICS
Volume 4, Issue 2, Pages -Publisher
WILEY
DOI: 10.1002/adtp.202000172
Keywords
anti-inflammatory drugs; antivirals; convalescent plasma; COVID-19; immune therapy; nanomedicines; vaccines
Categories
Funding
- ICMR-DHR
Ask authors/readers for more resources
The COVID-19 pandemic caused by SARS-CoV-2 has paralyzed the world, with advances in viral detection but limited progress in curative therapies. Potential future approaches include repurposed drugs, vaccine candidates, immune-modulators, and nanotechnology-based interventions to combat the deadly virus and facilitate multidrug therapeutics. Therapeutic candidates like remdesivir, dexamethasone, and antibody therapeutics are emerging as promising options in the fight against COVID-19.
The deadly pandemic, coronavirus disease 2019 (COVID-19), caused due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has paralyzed the world. Although significant methodological advances have been made in the field of viral detection/diagnosis with 251 in vitro diagnostic tests receiving emergency use approval by the US-FDA, little progress has been made in identifying curative or preventive therapies. This review discusses the current trends and potential future approaches for developing COVID-19 therapeutics, including repurposed drugs, vaccine candidates, immune-modulators, convalescent plasma therapy, and antiviral nanoparticles/nanovaccines/combinatorial nanotherapeutics to surmount the pandemic viral strain. Many potent therapeutic candidates emerging via drug-repurposing could significantly reduce the cost and duration of anti-COVID-19 drug development. Gene/protein-based vaccine candidates that could elicit both humoral and cell-based immunity would be on the frontlines to prevent the disease. Many emerging nanotechnology-based interventions will be critical in the fight against the deadly virus by facilitating early detection and enabling target oriented multidrug therapeutics. The therapeutic candidates discussed in this article include remdesivir, dexamethasone, hydroxychloroquine, favilavir, lopinavir/ritonavir, antibody therapeutics like gimsilumab and TJM2, anti-viral nanoparticles, and nanoparticle-based DNA and mRNA vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available